Eleven Biotherapeutics (NASDAQ:EBIO) Analyst Rating Consensus

Eleven Biotherapeutics (NASDAQ:EBIO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 1 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys.

Other Equity analysts have also commented on the company shares. Citigroup maintains its view on Eleven Biotherapeutics (NASDAQ:EBIO) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Citigroup lowers the price target from $1 per share to $0.4 per share on Eleven Biotherapeutics . The rating by the firm was issued on March 16, 2016.

Eleven Biotherapeutics (NASDAQ:EBIO) rose 4.95% or 0.11 points on Tuesday and made its way into the gainers of the day. After trading began at $2.18 the stock was seen hitting $2.39 as a peak level and $2.16 as the lowest level. The stock ended up at $2.33. The daily volume was measured at 1,236,148 shares. The 52-week high of the share price is $8 and the 52-week low is $0.2511. The company has a market cap of $46 million.

Shares of Eleven Biotherapeutics, Inc. rose by 2.64% in the last five trading days and 109.91% for the last 4 weeks. Eleven Biotherapeutics, Inc. is up 479.6% in the last 3-month period. Year-to-Date the stock performance stands at -22.59%.

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Companys lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *